Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02266485
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT02229773
Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Dr. Robert F. Casper
- Registration Number
- NCT02079974
- Locations
- 🇨🇦
Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
A Study of Evacetrapib in Japanese and Non-Japanese Participants
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01958489
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2014-04-21
- Target Recruit Count
- 117
- Registration Number
- NCT01845194
- Locations
- 🇩🇪
Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Goettingen, Germany
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 7
- Registration Number
- NCT01845428
- Locations
- 🇺🇸
Unc Kidney Center, Chapel Hill, North Carolina, United States
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Pure Erythroid Leukemia (M6b)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableUntreated Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Monocytic Leukemia (M5b)
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT01831232
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 160
- Registration Number
- NCT01816997
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Open Label Study for the Functional Characterization of Drug Metabolism and Transport
- Conditions
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Matthias Schwab
- Target Recruit Count
- 144
- Registration Number
- NCT01788254
- Locations
- 🇩🇪
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
🇩🇪Abteilung Klinische Pharmakologie, Tübingen, Germany
Pravastatin for Prevention of Preeclampsia
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2023-03-22
- Target Recruit Count
- 48
- Registration Number
- NCT01717586
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.